Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back (Q35128883)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 1, 2003

Language	Label	Description	Also known as
English	Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back	scientific article published on May 1, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

antineoplastic resistance

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12750693

3 January 2024

1 reference

10.1038/SJ.LEU.2402889

https://api.crossref.org/works/10.1038/SJ.LEU.2402889

3 January 2024

author name string

N. von Bubnoff

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12750693

3 January 2024

C. Peschel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12750693

3 January 2024

J. Duyster

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12750693

3 January 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12750693

3 January 2024

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

full work available at URL

https://www.nature.com/articles/2402889.pdf

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12750693

3 January 2024

https://www.nature.com/articles/2402889.pdf

1 reference

10.1038/SJ.LEU.2402889

https://api.crossref.org/works/10.1038/SJ.LEU.2402889

3 January 2024

https://www.nature.com/articles/2402889

1 reference

10.1038/SJ.LEU.2402889

https://api.crossref.org/works/10.1038/SJ.LEU.2402889

3 January 2024

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

829-838

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Chromosomal fragile sites and DNA amplification in drug-resistant cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

STI571: targeting BCR-ABL as therapy for CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

An activating mutation in the ATP binding site of the ABL kinase domain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Specific inhibition of bcr-abl gene expression by small interfering RNA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

Phase I trial of elactocin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

21 January 2018

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

7 January 2021

based on heuristic

inferred from DOI database lookup

Dermal and pulmonary inflammatory disease in E-selectin and P-selectin double-null mice is reduced in triple-selectin-null mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402889

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402889

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35128883&oldid=2197274319"